NF-E2 p18 (C-16): sc-477



The Power to Question

BACKGROUND

The nuclear DNA binding protein NF-E2 regulates expression of globulin genes in developing erythroid cells through interaction with upstream AP-1-like recognition sites. More specifically, NF-E2 recognizes a site containing an intact AP-1 binding motif, preceded by a G residue two base pairs upstream. NF-E2 is an obligate heterodimer composed of NF-E2 p45 and NF-E2 p18. NF-E2 p18, also known as NF-E2U or MafK, is a ubiquitously expressed component that is related to the v-Maf oncogene. It contains a basic leucine zipper domain that functions in DNA binding and dimerization. In addition, NF-E2 p18 may play a role in erythroid differentiation. The major component of NF-E2 is a polypeptide, designated NF-E2 p45, that belongs to the basic region leucine zipper family of transcription factors. This subunit of NF-E2 is specifically expressed at low level in hematopoietic progenitor cells and differentiated cells of the erythroid, megakaryocyte and mast cell lineages.

CHROMOSOMAL LOCATION

Genetic locus: MAFK (human) mapping to 7p22.3; Mafk (mouse) mapping to 5 G2.

SOURCE

NF-E2 p18 (C-16) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the C-terminus of NF-E2 p18 of mouse origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-477 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

Available as TransCruz reagent for Gel Supershift and ChIP applications, sc-477 X, 200 μ g/0.1 ml.

APPLICATIONS

NF-E2 p18 (C-16) is recommended for detection of NF-E2 p18 (also designated MafK) of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μg per 100-500 μg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffinembedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for NF-E2 p18 siRNA (h): sc-38103, NF-E2 p18 siRNA (m): sc-38104, NF-E2 p18 shRNA Plasmid (h): sc-38103-SH, NF-E2 p18 shRNA (h) Lentiviral Particles: sc-38103-V and NF-E2 p18 shRNA (m) Lentiviral Particles: sc-38104-V.

NF-E2 p18 (C-16) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of NF-E2 p18: 18 kDa.


RESEARCH USE


For research use only, not for use in diagnostic procedures.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA







NF-E2 p18 (C-16): sc-477. Immunofluorescence staining of methanol-fixed HeLa cells showing nuclear localization (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human placenta tissue showing nuclear and cytoplasmic staining of decidual cells (B).

SELECT PRODUCT CITATIONS

- Kotkow, K.J., et al. 1996. Complexity of the erythroid transcription factor NF-E2 as revealed by gene targeting of the mouse p18 NF-E2 locus. Proc. Natl. Acad. Sci. USA 93: 3514-3518.
- 2. Brand, M., et al. 2004. Dynamic changes in transcription factor complexes during erythroid differentiation revealed by quantitative proteomics. Nat. Struct. Mol. Biol. 11: 73-80.
- Duvoix, A., et al. 2004. Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. Cancer Lett. 216: 207-219.
- Bouzinba-Segard, H., et al. 2006. Accumulation of small murine minor satellite transcripts leads to impaired centromeric architecture and function. Proc. Natl. Acad. Sci. USA 103: 8709-8714.
- 5. De Gobbi, M., et al. 2007. Tissue-specific histone modification and transcription factor binding in α globin gene expression. Blood 110: 4503-4510.
- Vernimmen, D., et al. 2007. Long-range chromosomal interactions regulate the timing of the transition between poised and active gene expression. EMBO J. 26: 2041-2051.
- 7. Demers, C., et al. 2007. Activator-mediated recruitment of the MLL2 methyltransferase complex to the β -globin locus. Mol. Cell 27: 573-584.
- 8. Du, M.J., et al. 2008. MafK/NF-E2 p18 is required for β -globin genes activation by mediating the proximity of LCR and active β -globin genes in MEL cell line. Int. J. Biochem. Cell Biol. 40: 1481-1493.
- 9. Zhou, Z., et al. 2010. USF and NF-E2 cooperate to regulate the recruitment and activity of RNA polymerase II in the β -globin gene locus. J. Biol. Chem. 285: 15894-15905.
- Anguita, E., et al. 2010. GFI1B controls its own expression binding to multiple sites. Haematologica 95: 36-46.